Study establishes role for gefitinib in Asian nonsmokers with lung cancer
The targeted therapy gefitinib should be considered a first-line therapy for non-smoking Asian patients with adenocarcinoma of the lung, one of the most common types of lung cancer, suggests a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm. Asia has a high proportion of lung cancer patients who are non-smokers, a significant proportion of whom develop a form of cancer known as adenocarcinoma.
"Around 50% to 60% of this population have tumors with mutations in the epidermal growth factor receptor, and we know that patients with such mutations have a significantly better treatment outcome with gefitinib," said researcher Prof. Tony Mok from the Chinese University of Hong Kong.
"Currently, gefitinib and other EGFR tyrosine kinase inhibitors are considered as second line therapy for advanced non-small-cell lung cancers, meaning that the drugs should only be used after cancers fail to respond to the standard cytotoxic chemotherapy."
Prof. Mok's group studied 1,217 lung cancer patients who had never received chemotherapy and had never smoked or were light ex-smokers. Half the group was treated with gefitinib 250 mg/day or a combination of carboplatin and paclitaxel.
Over 22 months of follow-up, the researchers found that gefitinib was more tolerable and resulted in a greater likelihood of response.
"We have demonstrated better treatment outcomes with gefitinib over standard chemotherapy as first-line therapy for this clinically selected population," Prof. Mok said. "Our study has established the role of gefitinib as one of the standard first-line therapies for a clinically selected group of non-/light smokers with adenocarcinoma."
Source: European Society for Medical Oncology
Articles on the same topic
- New drug substantially extends survival in pancreatic cancerTue, 16 Sep 2008, 14:44:35 UTC
- European disparities in access to cancer drugsTue, 16 Sep 2008, 14:44:19 UTC
- Promising new treatment option for women with recurrent ovarian cancerMon, 15 Sep 2008, 15:17:00 UTC
- Investigational drug shows promise in ovarian cancerMon, 15 Sep 2008, 14:29:29 UTC
- Ovarian cancer drug trial reveals promising new treatmentMon, 15 Sep 2008, 14:29:17 UTC
Other sources
- New Drug Substantially Extends Survival In Pancreatic Cancerfrom Science DailyWed, 17 Sep 2008, 19:14:24 UTC
- Investigational drug shows promise in ovarian cancerfrom Biology News NetWed, 17 Sep 2008, 12:14:41 UTC
- New ovarian cancer treatment is developedfrom UPITue, 16 Sep 2008, 19:07:12 UTC
- New drug substantially extends survival in pancreatic cancerfrom PhysorgTue, 16 Sep 2008, 14:43:28 UTC
- Investigational drug shows promise in ovarian cancerfrom Biology News NetMon, 15 Sep 2008, 22:21:58 UTC
- Hope, confusion in hunt for ovarian cancer testsfrom PhysorgMon, 15 Sep 2008, 20:28:33 UTC
- Hope, confusion in hunt for ovarian cancer testsfrom AP HealthMon, 15 Sep 2008, 19:42:56 UTC
- Investigational drug shows promise in ovarian cancerfrom PhysorgMon, 15 Sep 2008, 15:14:57 UTC
- Ovarian Cancer Drug Trial Reveals Promising New Treatmentfrom Science DailyMon, 15 Sep 2008, 14:28:18 UTC
- Investigational Drug Shows Promise In Ovarian Cancerfrom Science DailyMon, 15 Sep 2008, 14:28:12 UTC